function. Sequence analysis was conducted using the ORF Finder and the BLASTp functions at NCBI. For each isolate, multiresistance gene cluster-carrying contigs ranging in size between 9613 bp and 9690 bp were obtained. They comprised the region from the aadE gene to downstream of lnu(B). A comparison with the 17577 bp sequence of the cluster located on the multiresistance plasmid pV7037 (GenBank accession number JX560992) revealed a single nucleotide exchange (A C) in the MRSA CC398 isolate at position 9474 in the non-coding region between spw and orf4. An additional nucleotide exchange (A G), which, however, did not change the amino acid sequence, was seen in all 12 isolates at position 10071 within orf4. All CC9 isolates carried a transposase gene downstream of the gene lnu(B). The CC398 isolate exhibited at this position two genes coding for a resolvase and a nucleotidyltransferase with greatest amino acid identities of 99.5% and 100%, respectively, with the corresponding proteins from Enterococcus faecium Aus0085 plasmid p3 (GenBank accession number NC_021988.1). In all cases, the repeatedly negative results of conjugation, protoplast transformation and electrotransformation experiments suggested that the cluster was located in the chromosomal DNA, as previously seen for the majority of the Chinese porcine MRSA CC9 isolates and the Spanish MRSA ST398 and MSSA ST9 isolates of human origin. 1, 2 In conclusion, a large part of the pV7037-associated multiresistance gene cluster, including the novel resistance genes lsa(E) and spw, was identified in MRSA CC9 isolated from different food samples and a butcher in Hong Kong as well as from a single MRSA CC398 of human origin in Germany. These and previous observations suggest that a multiresistance gene cluster, closely related to the one that has recently been detected in enterococci of human and porcine origin, 4 has been acquired by MRSA/MSSA CC9 and CC398 several times on different occasions in Europe and Asia.
Sir, The New Delhi metallo-b-lactamase (NDM-1) was initially identified in Escherichia coli and Klebsiella pneumoniae isolates in Sweden, from a patient previously hospitalized in India. 1 To date, NDM producers in Latin America have been scarce, and associated with species of Enterobacteriaceae from Guatemala, Mexico, Colombia and Brazil, although in Honduras it was reported in Acinetobacter baumannii.
2 -6 Here, we report two genetically unrelated NDM-1-producing Acinetobacter pittii isolates identified in Paraguay.
Since 1996, the Pan American Health Organization (PAHO) has supported a regional surveillance system, the Antimicrobial Resistance Surveillance Network in Latin America (ReLAVRA), that includes 794 laboratories from 20 Latin American countries, including their respective reference laboratories. 7 This network provides reliable, timely and reproducible microbiological data in order to improve patient care. A regional protocol for the detection of carbapenemases has been harmonized and implemented through ReLAVRA. Briefly, metallo-b-lactamase (MBL) production is suspected in isolates that exhibit decreased susceptibility to carbapenems (CLSI criteria) and a positive synergy test result between a disc containing 10 mg of imipenem and a disc containing 750 mg of EDTA plus 1900 mg of sodium thioglycolate. 8 During 2012, following the ReLAVRA algorithm, the National Health Laboratory of Paraguay confirmed an MBL phenotype in two Acinetobacter spp. isolates recovered from a single hospital. This phenotype had not previously been observed in Acinetobacter spp. from Paraguay. The first case was a 7-year-old patient admitted in July because of acute encephalitis. After 2 months of hospitalization, an Enterobacter cloacae extendedspectrum b-lactamase producer and Acinetobacter M15274 were recovered from the CSF obtained through a ventricular shunt. The patient received multiple treatment regimens, including trimethoprim/sulfamethoxazole, ciprofloxacin and amikacin, which resulted in clinical and microbiological cure. The patient died after 4 months of hospitalization due to non-infectious causes. The second case was a 2-year-old patient with a diagnosis of acute lymphocytic leukaemia who was admitted in November. Two weeks later the patient developed sepsis, and Acinetobacter M15373 was isolated from a blood culture. The patient showed clinical improvement after treatment with meropenem plus amikacin and was discharged alive after 50 days. Both patients were hospitalized in the same oncology ward but 4 months apart from each other. Remarkably, the patients had no history of travelling. Transconjugant strains of A. pittii M15373. c MICs were determined using agar dilution; MICs of other antibiotics were determined using the Vitek 2C (AST-N082 card). d EDTA at a fixed concentration of 0.4 mM. The bla VIM-11 -producing Pseudomonas aeruginosa M5109 was used for quality control purposes.
Strains were submitted to the Regional Reference Laboratory (Servicio Antimicrobianos, INEI, ANLIS 'Dr Carlos G. Malbrá n') for further characterization. Strains were identified as A. pittii by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF; Bruker, Germany); the 10 most probable database matches were all consistent with A. pittii. Antimicrobial susceptibility testing revealed an identical resistance profile in both A. pittii isolates, except for ampicillin/sulbactam and quinolones (Table 1) . EDTA reduced the carbapenem MICs by at least three dilutions in both strains, suggesting the presence of MBLs (Table 1) . The modified Hodge test gave negative results with meropenem but was positive (weakly) with imipenem.
In both isolates, PCR screening followed by DNA sequencing detected the presence of bla NDM-1 . PCRs targeting other b-lactamase genes (bla VIM , bla IMP , bla SPM , bla KPC , bla OXA-23 , bla OXA-24/40 , bla OXA-48 , bla OXA-51 , bla OXA-58 , bla OXA-143 , bla CTX-M , bla SHV and bla TEM ) were negative. Sequencing of a 2.5 kb fragment surrounding bla NDM-1 from both strains revealed 100% identity to the sequence reported for Acinetobacter lwoffii, where ISAba125 was located upstream of bla NDM-1 , followed by DtrpF and tat. 9, 10 The genes that follow to the 3 ′ end, DgroES, groEL, ISCR27 and the second ISAba25 were PCR mapped, revealing a Tn125 composite transposon as previously reported in A. pittii.
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ApaI PFGE studies revealed that the A. pittii isolates were not clonally related (.10 bands of difference in the macrorestriction pattern). Multilocus sequence typing (MLST) was performed according to the MLST Database (http://www.pasteur.fr/ recherche/genopole/PF8/mlst/). M15274 and M15373 displayed unique and novel sequence types (STs), designated ST320 and ST321, respectively. M15274 and M15373 shared only the rplB allele, confirming that they were genetically unrelated. Furthermore, these STs branched with other reported isolates belonging to the A. pittii genomic species, confirming the MALDI-TOF results.
The bla NDM-1 gene was transferred by biparental conjugation to either sodium azide-resistant E. coli J53 or A. baumannii ATCC 19606 from M15373 but not from M15274, conferring non-susceptibility to carbapenems on the recipient strain (Table 1) . S1 nuclease digestion showed that both A. pittii and the transconjugant strains harboured a single plasmid of 54 kb that hybridized with the bla NDM probe. Plasmids gave negative results for all the Inc groups when assessed by PCR replicon typing. 12 Additionally, further characterization of 23 contemporary carbapenem-resistant Acinetobacter spp. isolated in the same institution from November 2012 to March 2013 (clinical strains and patient swab samples) revealed a lack of MBL production and matched A. baumannii by MALDI-TOF.
A. pittii has recently been recognized as a key organism for the dissemination of NDM, since it has been associated with the dispersal of this carbapenemase in such diverse scenarios as food of animal origin and sewage, and has been responsible for both sporadic human infection and large outbreaks in hospital units. 10, 13, 14 Until now, non-baumannii Acinetobacter spp. expressing NDM have not been described in the American continent. These A. pittii clinical isolates are the first characterized NDM-1 producers from Paraguay. The origin of NDM-1-positive A. pittii in Paraguay remains unclear, since no history of travel to the suggested reservoirs of NDM was established for either patient. Our finding of bla NDM-1 on plasmids of identical 54 kb size in A. pittii strains with a heterogeneous clonal background suggests that bla NDM-1 most likely spread by the transfer of plasmids in A. pittii. Recent published data suggest that A. pittii could act as a potential NDM reservoir for Enterobacteriaceae based on the ease of plasmid transfer to E. coli, 11 as observed in one of the isolates reported here. Despite this ability, no further cases of NDM producers have so far been observed in the hospital.
In conclusion, the emergence of NDM in A. pittii constitutes a public health concern in Latin America, highlighting the relevance of an integrated surveillance of carbapenemase producers. Sir, In December 2013, a carbapenem-resistant Acinetobacter baumannii was recovered from routine skin and rectum swabs from a patient during admission screening. The patient had been on a repatriation transport to Australia after previous hospitalization in Greece due to Waterhouse -Friderichsen syndrome as a result of severe meningococcal septicaemia. At the stop-over in Germany he presented with a decreased level of consciousness, multiple decubitus ulcers (grade IV) and reduced general condition and was admitted to the Internal Medicine Intensive Care Unit at the Hospital of the Johann Wolfgang von Goethe University in Frankfurt. Infection parameters were elevated, although a definite infection focus could not be established. Empirical anti-infective therapy with colistin, meropenem, linezolid, fosfomycin and caspofungin was initiated. The patient recovered after 1 week and could be transferred.
Susceptibility testing of the A. baumannii isolate using the Etest method revealed non-susceptibility to all antibiotic groups where breakpoints have been defined for Acinetobacter spp. by either EUCAST or CLSI (penicillins/b-lactamase inhibitors, extended-spectrum cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, tetracyclines, folate pathway inhibitors and polymyxins), including colistin, with an MIC of 128 mg/L (Table 1) .
1,2 The A. baumannii isolate was thus categorized as pan drug-resistant (PDR) in accordance with the guidelines defined by the international expert committee of the European Centre for Disease Prevention and Control (ECDC) and CDC. 3 First reports of PDR A. baumannii emerged in 2001 and a nosocomial outbreak with PDR A. baumannii in 2002 was reported from Spain. 4, 5 However, in many other studies the term PDR was used inappropriately since important antibiotics such as colistin and 
